Glaukos (NYSE:GKOS) Given New $139.00 Price Target at BTIG Research

Glaukos (NYSE:GKOS - Free Report) had its target price lifted by BTIG Research from $131.00 to $139.00 in a report issued on Wednesday, Benzinga reports. They currently have a buy rating on the medical instruments supplier's stock.

A number of other equities analysts have also weighed in on GKOS. Piper Sandler boosted their price objective on Glaukos from $110.00 to $140.00 and gave the stock an overweight rating in a research note on Thursday, August 1st. Morgan Stanley upped their price target on Glaukos from $100.00 to $120.00 and gave the company an equal weight rating in a research note on Monday, July 15th. StockNews.com raised Glaukos from a sell rating to a hold rating in a research note on Friday, August 2nd. Truist Financial reissued a buy rating and set a $145.00 target price (up previously from $141.00) on shares of Glaukos in a research note on Thursday, August 1st. Finally, Needham & Company LLC increased their target price on Glaukos from $131.00 to $137.00 and gave the stock a buy rating in a research note on Thursday, August 1st. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of Moderate Buy and an average price target of $128.45.

Glaukos Trading Up 0.1 %

NYSE GKOS traded up $0.13 on Wednesday, reaching $135.39. 296,658 shares of the company were exchanged, compared to its average volume of 586,973. The business's fifty day moving average price is $121.40 and its 200 day moving average price is $107.16. The stock has a market capitalization of $6.82 billion, a P/E ratio of -47.01 and a beta of 1.05. The company has a current ratio of 5.48, a quick ratio of 4.68 and a debt-to-equity ratio of 0.19. Glaukos has a fifty-two week low of $59.22 and a fifty-two week high of $136.36.

Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings data on Wednesday, July 31st. The medical instruments supplier reported ($0.52) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.52). The company had revenue of $95.70 million for the quarter, compared to analyst estimates of $88.86 million. Glaukos had a negative return on equity of 22.51% and a negative net margin of 47.39%. The firm's revenue for the quarter was up 19.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.55) earnings per share. Analysts forecast that Glaukos will post -2.25 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Aimee S. Weisner sold 25,000 shares of the stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $120.00, for a total value of $3,000,000.00. Following the transaction, the director now owns 30,119 shares in the company, valued at approximately $3,614,280. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, COO Joseph E. Gilliam sold 2,500 shares of the firm's stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $113.50, for a total transaction of $283,750.00. Following the transaction, the chief operating officer now owns 101,845 shares in the company, valued at approximately $11,559,407.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Aimee S. Weisner sold 25,000 shares of the firm's stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $120.00, for a total value of $3,000,000.00. Following the transaction, the director now owns 30,119 shares in the company, valued at approximately $3,614,280. The disclosure for this sale can be found here. Insiders have sold a total of 46,000 shares of company stock worth $5,550,740 in the last quarter. 6.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. National Bank of Canada FI purchased a new position in Glaukos during the 4th quarter worth approximately $46,000. GAMMA Investing LLC acquired a new stake in Glaukos during the 4th quarter worth approximately $55,000. Quadrant Capital Group LLC lifted its position in Glaukos by 54.8% during the 4th quarter. Quadrant Capital Group LLC now owns 929 shares of the medical instruments supplier's stock worth $74,000 after acquiring an additional 329 shares during the period. Caldwell Sutter Capital Inc. lifted its position in Glaukos by 5,860.0% during the 1st quarter. Caldwell Sutter Capital Inc. now owns 1,490 shares of the medical instruments supplier's stock worth $140,000 after acquiring an additional 1,465 shares during the period. Finally, Fifth Third Wealth Advisors LLC acquired a new stake in Glaukos during the 2nd quarter worth approximately $187,000. Hedge funds and other institutional investors own 99.04% of the company's stock.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.